Apitolisib (GDC-0980, RG7422, GNE 390, GDC0980, RG-7422, GNE390)是可口服的I类PI3K选择性抑制剂，作用于PI3Kα/β/δ/γ的IC₅₀分别为5 nM、27 nM、7 nM和14 nM，具有抗癌活性。

参考文献

[1] Sutherlin DP, et al. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem. 2011 Nov 10;54(21):7579-87.

[2] Wallin JJ, et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther. 2011 Dec;10(12):2426-36.

冰袋运输。粉末直接保存于-20℃，有效期3年。建议分装后-20℃干燥保存，避免反复冻融。